Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2024, 6(11); doi: 10.25236/IJFM.2024.061106.

Timing of radiotherapy after radical prostatectomy adjuvant radiotherapy OR salvage radiotherapy

Author(s)

Hongbin Deng, Xinyi Cao, Junming Zhu

Corresponding Author:
Hongbin Deng
Affiliation(s)

The Frist Affiliated Hospital of Chongqing Medical University, Chongqing, China

Abstract

Radical prostatectomy is currently one of the primary treatments for localized prostate cancer. However, some patients experience biochemical recurrence after the procedure, which can lead to disease progression and eventual death. The risk of biochemical recurrence is higher in patients with high risk factors, including extraperitoneal tumor invasion, positive surgical margins, and a high Gleason score. Previous research has demonstrated that adjuvant radiotherapy after radical prostatectomy can reduce the risk of biochemical recurrence and improve metastasis-free survival. However, it also increases the risk of urinary tract and intestinal-related side effects and may result in overtreatment of patients who do not experience biochemical recurrence. Salvage radiotherapy, which is administered following biochemical recurrence, can mitigate the risk of overtreatment in patients without biochemical recurrence. Additionally, some studies have pointed out that salvage radiotherapy offers comparable survival benefits to adjuvant radiotherapy while reducing toxic side effects. Therefore, opting for salvage radiotherapy instead of adjuvant radiotherapy after radical prostatectomy might be a reasonable option.

Keywords

Prostate cancer; Biochemical recurrence; Adjuvant radiotherapy (ART); radical prostatectomy (RP)

Cite This Paper

Hongbin Deng, Xinyi Cao, Junming Zhu. Timing of radiotherapy after radical prostatectomy adjuvant radiotherapy OR salvage radiotherapy. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 11: 35-41. https://doi.org/10.25236/IJFM.2024.061106.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–249.

[2] Axén E, Stranne J, Månsson M, Holmberg E, Arnsrud Godtman R. Biochemical recurrence after radical prostatectomy – a large, comprehensive, population-based study with long follow-up. Scandinavian Journal of Urology 2022;56(4):287–292.

[3] Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181(3):956–962.

[4] Bolla M, Poppel H van, Tombal B, Vekemans K, Pozzo LD, Reijke TM de, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). The Lancet 2012;380(9858):2018–2027.

[5] Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27(18):2924–2930.

[6] Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, et al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. European Urology 2019; 76(5): 586–595.

[7] Latorzeff I, Le Guevelou J, Sargos P. Radiation therapy post radical prostatectomy: who, when and why? Curr Opin Support Palliat Care 2023;17(1):47–54.

[8] Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177(2):540–545.

[9] Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol 2016; 195(6): 1754–1759.

[10] King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012;84(1):104–111.

[11] Mir MC, Li J, Klink JC, Kattan MW, Klein EA, Stephenson AJ. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. Eur Urol 2014;66(2):204–210. 

[12] Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965–974.

[13] Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61(2):365–369.

[14] Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020; 21(10):1331–1340.

[15] Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020;21(10):1341–1352.

[16] Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol 2024;:S0923-7534(24)00105–4.

[17] Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, Ian LH, et al. Prostate cancer in Asia: A collaborative report. Asian J Urol 2014;1(1):15–29.

[18] Zhang L, Liu X, Xia R, Chen F, Wang X, Bao J, et al. Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations. Pathology - Research and Practice 2022;234:153933.

[19] Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012;61(1):11–25.

[20] Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet 2022; 399(10338):1886–1901.

[21] Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 2019;20(12):1740–1749.

[22] Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology 2020;6(5):735–743.

[23] Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. The Lancet 2024; 403(10442):2416–2425.

[24] Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. JAMA 2005;294(4):433–439.

[25] Venclovas Z, Jievaltas M, Milonas D. Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients. Front Oncol 2019;9:1286.

[26] Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113(11):3075–3099.

[27] Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61(2):365–369.

[28] Chung JH, Jeong JY, Lee JY, Song W, Kang M, Sung HH, et al. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value. PLoS One 2021;16(5):e0249709.

[29] Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. Eur Urol Oncol 2018;1(5):378–385.

[30] D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M-H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95(18):1376–1383.

[31] Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting fifteen-year cancer-specific mortality based on the pathological features of prostate cancer. J Urol 2011;185(3):869–875.